当前位置: 首页 >> 检索结果
4361. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
来源: Circulation. 1998年97卷24期2386-95页
Unstable angina and non-Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and in combination with heparin in patients with these conditions to select the most promising lamifiban regimen for subsequent evaluation.
4362. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
作者: W C Yu.;S A Chen.;S H Lee.;C T Tai.;A N Feng.;B I Kuo.;Y A Ding.;M S Chang.
来源: Circulation. 1998年97卷23期2331-7页
Atrial fibrillation (AF) has been shown to shorten the atrial effective refractory period (ERP) and make the atrium more vulnerable to AF. This study investigated the effect of atrial rate and antiarrhythmic drugs on ERP shortening induced by tachycardia.
4363. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Neutral endopeptidase (NEP) degrades vasoactive peptides, including the natriuretic peptides, angiotensin II, and endothelin-1. Systemic inhibition of NEP does not consistently lower blood pressure, even though it increases natriuretic peptide concentrations and causes natriuresis and diuresis. We therefore investigated the direct effects of local inhibition of NEP on forearm resistance vessel tone.
4364. Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation.
作者: K Kugiyama.;M Ohgushi.;T Motoyama.;O Hirashima.;H Soejima.;K Misumi.;M Yoshimura.;H Ogawa.;S Sugiyama.;H Yasue.
来源: Circulation. 1998年97卷23期2299-301页
Oxygen free radicals have been shown to cause endothelial vasomotor dysfunction. This study examined the effect of reduced glutathione (GSH), an antioxidant, on human coronary circulation.
4365. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension.
Essential hypertension is associated with impaired endothelium-dependent vasodilation. Inactivation of endothelium-derived nitric oxide by oxygen free radicals participates in endothelial dysfunction in experimental hypertension. To test this hypothesis in humans, we evaluated the effect of antioxidant vitamin C on endothelium-dependent responses in essential hypertensive patients.
4366. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial.
作者: A I Mushlin.;W J Hall.;J Zwanziger.;E Gajary.;M Andrews.;R Marron.;K H Zou.;A J Moss.
来源: Circulation. 1998年97卷21期2129-35页
The recently reported Multicenter Automatic Defibrillator Implantation Trial (MADIT) showed improved survival in selected asymptomatic patients with coronary disease and nonsustained ventricular tachycardia. The economic consequences of defibrillator management in this patient population are unknown.
4367. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans.
作者: A Lerman.;J C Burnett.;S T Higano.;L J McKinley.;D R Holmes.
来源: Circulation. 1998年97卷21期2123-8页
Coronary endothelial dysfunction is characterized by an imbalance between endothelium-derived vasodilating and vasoconstricting factors and coronary vasoconstriction in response to the endothelium-dependent vasodilator acetylcholine. Thus, the present double-blind, randomized study was designed to test the hypothesis that long-term, 6-month supplementation of L-arginine, the precursor of the endothelium-derived vasodilator NO, reverses coronary endothelial dysfunction to acetylcholine in humans with nonobstructive coronary artery disease.
4368. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial.
作者: J J Mahmarian.;L A Moyé.;D A Chinoy.;R F Sequeira.;G B Habib.;W J Henry.;A Jain.;B R Chaitman.;C S Weng.;H Morales-Ballejo.;C M Pratt.
来源: Circulation. 1998年97卷20期2017-24页
Nitrates are widely used in the treatment of angina in patients with acute myocardial infarction (AMI). Short-term administration prevents left ventricular (LV) dilation and infarct expansion. However, little information is available regarding their long-term effects on LV remodeling in patients surviving Q-wave AMI.
4369. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.
C-reactive protein (CRP) is a sensitive marker of inflammation, and elevated levels have been associated with future risk of myocardial infarction (MI). However, whether measurement of CRP adds to the predictive value of total cholesterol (TC) and HDL cholesterol (HDL-C) in determining risk is uncertain.
4370. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
作者: N S Kleiman.;A M Lincoff.;D J Kereiakes.;D P Miller.;F V Aguirre.;K M Anderson.;H F Weisman.;R M Califf.;E J Topol.
来源: Circulation. 1998年97卷19期1912-20页
After angioplasty, major complications and ischemic events occur more frequently in diabetic than nondiabetic patients. To determine whether treatment with abciximab is effective in reducing these events in diabetics, we analyzed characteristics and outcomes of diabetic patients enrolled in a large multicenter study (EPILOG).
4371. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
作者: S MacMahon.;N Sharpe.;G Gamble.;H Hart.;J Scott.;J Simes.;H White.
来源: Circulation. 1998年97卷18期1784-90页
Cholesterol lowering in patients with above-average cholesterol levels has been shown to reduce the progression of atherosclerosis and lower the risk of coronary heart disease events. However, there has been uncertainty about the effects of cholesterol lowering in patients with average or below-average cholesterol levels.
4372. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.
作者: A M Ross.;K S Coyne.;E Moreyra.;J S Reiner.;S W Greenhouse.;P L Walker.;M L Simoons.;Y C Draoui.;R M Califf.;E J Topol.;F Van de Werf.;C F Lundergan.
来源: Circulation. 1998年97卷16期1549-56页
Reperfusion therapy for myocardial infarction, understood to reduce mortality by preserving left ventricular function, was initially expected to provide increasing benefits over time. Surprisingly, large controlled thrombolysis trials demonstrated maximum benefit at 4 to 6 weeks with no subsequent increased treatment advantage. Such studies, however, compared groups by assigned treatment, not physiological effectiveness.
4373. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
作者: D B Mark.;P A Cowper.;S D Berkowitz.;L Davidson-Ray.;E R DeLong.;A G Turpie.;R M Califf.;B Weatherley.;M Cohen.
来源: Circulation. 1998年97卷17期1702-7页
In the ESSENCE trial, subcutaneous low-molecular-weight heparin (enoxaparin) reduced the 30-day incidence of death, myocardial infarction, and recurrent angina relative to intravenous unfractionated heparin in 3171 patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction). No increase in major bleeding was seen.
4374. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
作者: M A Mascelli.;E T Lance.;L Damaraju.;C L Wagner.;H F Weisman.;R E Jordan.
来源: Circulation. 1998年97卷17期1680-8页
The glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is approved for use in high-risk percutaneous coronary interventions. The purpose of the present study was to establish the pharmacodynamic profile and platelet-bound life span of abciximab.
4375. Comparison between noninvasive indices of baroreceptor sensitivity and the phenylephrine method in post-myocardial infarction patients.
作者: M V Pitzalis.;F Mastropasqua.;A Passantino.;F Massari.;L Ligurgo.;C Forleo.;C Balducci.;F Lombardi.;P Rizzon.
来源: Circulation. 1998年97卷14期1362-7页
Depressed baroreflex sensitivity obtained by means of a phenylephrine test plays a prognostic role in patients with a previous myocardial infarction. Our purpose was to evaluate the correlation and agreement between the baroreflex sensitivity obtained with phenylephrine and that obtained by two noninvasive methods: the alpha-index and sequence analysis.
4376. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.
作者: M Kyriakidis.;F Triposkiadis.;J Dernellis.;A E Androulakis.;P Mellas.;G A Kelepeshis.;J E Gialafos.
来源: Circulation. 1998年97卷14期1342-7页
Left ventricular (LV) diastolic function and coronary flow are impaired in hypertrophic obstructive cardiomyopathy (HOCM). This study was designed to evaluate the impact of cardiac and circulatory ACE inhibition on such derangements.
4377. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo.
作者: A Gries.;C Bode.;K Peter.;A Herr.;H Böhrer.;J Motsch.;E Martin.
来源: Circulation. 1998年97卷15期1481-7页
Recent data suggest that inhaled NO can inhibit platelet aggregation. This study investigates whether inhaled NO affects the expression level and avidity of platelet membrane receptors that mediate platelet adhesion and aggregation.
4378. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease.
作者: S C Chuah.;P A Pellikka.;V L Roger.;R B McCully.;J B Seward.
来源: Circulation. 1998年97卷15期1474-80页
Increasingly, dobutamine stress echocardiography has been used for detection of coronary artery disease. Less information exists regarding the incremental prognostic value of the test, including semiquantitative wall scoring, compared with clinical and rest echocardiographic variables.
4379. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).
作者: T R Pedersen.;A G Olsson.;O Faergeman.;J Kjekshus.;H Wedel.;K Berg.;L Wilhelmsen.;T Haghfelt.;G Thorgeirsson.;K Pyörälä.;T Miettinen.;B Christophersen.;J A Tobert.;T A Musliner.;T J Cook.
来源: Circulation. 1998年97卷15期1453-60页
The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310 mg/dL) with triglycerides < or =2.5 mmol/L (220 mg/dL) to simvastatin 20 to 40 mg or placebo once daily. Over the median follow-up period of 5.4 years, one or more major coronary events (MCEs) occurred in 622 (28%) of the 2223 patients in the placebo group and 431 (19%) of the 2221 patients in the simvastatin group (34% risk reduction, P<.00001). Simvastatin produced substantial changes in several lipoprotein components, which we have attempted to relate to the beneficial effects observed.
4380. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
作者: F M Sacks.;L A Moyé.;B R Davis.;T G Cole.;J L Rouleau.;D T Nash.;M A Pfeffer.;E Braunwald.
来源: Circulation. 1998年97卷15期1446-52页
Although LDL lowering has been shown to reduce recurrent coronary events in patients with coronary heart disease, little direct information is available on the extent of LDL lowering required to achieve this outcome.
|